Principal Financial Group
EGRX

Principal Financial Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Principal Financial Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-68,620
Closed -$1.95M – 2519
2023
Q1 		$1.95M Sell
68,620
-2,285
-3% -$67.8K ﹤0.01% 1768
2022
Q4 		$2.07M Sell
70,905
-384
-0.5% -$12.2K ﹤0.01% 1756
2022
Q3 		$1.88M Sell
71,289
-10,970
-13% -$403K ﹤0.01% 1721
2022
Q2 		$3.65M Sell
82,259
-936
-1% -$43K ﹤0.01% 1660
2022
Q1 		$4.12M Sell
83,195
-4,702
-5% -$226K ﹤0.01% 1724
2021
Q4 		$4.48M Sell
87,897
-10,719
-11% -$555K ﹤0.01% 1707
2021
Q3 		$5.5M Sell
98,616
-2,370
-2% -$117K ﹤0.01% 1654
2021
Q2 		$4.32M Sell
100,986
-9,653
-9% -$398K ﹤0.01% 1752
2021
Q1 		$4.62M Buy
110,639
+2,286
+2% +$106K ﹤0.01% 1687
2020
Q4 		$5.05M Buy
108,353
+1,022
+1% +$47.8K ﹤0.01% 1555
2020
Q3 		$4.56M Buy
107,331
+20,781
+24% +$909K ﹤0.01% 1487
2020
Q2 		$4.15M Sell
86,550
-249
-0.3% -$12.4K ﹤0.01% 1498
2020
Q1 		$3.99M Sell
86,799
-3,131
-3% -$157K ﹤0.01% 1376
2019
Q4 		$5.4M Buy
89,930
+10,160
+13% +$606K ﹤0.01% 1512
2019
Q3 		$4.51M Sell
79,770
-2,869
-3% -$161K ﹤0.01% 1551
2019
Q2 		$4.6M Sell
82,639
-162
-0.2% -$8.45K ﹤0.01% 1556
2019
Q1 		$4.18M Sell
82,801
-6,488
-7% -$289K ﹤0.01% 1604
2018
Q4 		$3.6M Sell
89,289
-669
-0.7% -$34.5K ﹤0.01% 1600
2018
Q3 		$6.24M Buy
89,958
+25,120
+39% +$1.9M 0.01% 1533
2018
Q2 		$4.91M Sell
64,838
-9,047
-12% -$569K ﹤0.01% 1599
2018
Q1 		$3.89M Buy
73,885
+2,436
+3% +$142K ﹤0.01% 1626
2017
Q4 		$3.82M Sell
71,449
-1,504
-2% -$83.7K ﹤0.01% 1638
2017
Q3 		$4.35M Buy
72,953
+4,963
+7% +$300K ﹤0.01% 1595
2017
Q2 		$5.36M Buy
67,990
+5,954
+10% +$487K 0.01% 1526
2017
Q1 		$5.14M Buy
62,036
+3,879
+7% +$288K 0.01% 1522
2016
Q4 		$4.61M Buy
58,157
+19
+0% +$1.38K 0.01% 1541
2016
Q3 		$4.07M Buy
+58,138
New +$3.22M 0.01% 1525

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group's EGRX Position: Q2 2023 in Review

Principal Financial Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 68,620 shares — an estimated $1.95M sold.

Principal Financial Group first reported a position in EGRX in Q3 2016 and held it in 27 quarters. The position peaked at $6.24M in Q3 2018. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Principal Financial Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Principal Financial Group sold 68,620 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.95M.
  • Principal Financial Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 27 quarters.
  • Principal Financial Group's Eagle Pharmaceuticals, Inc. position peaked at $6.24M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.